Shots:
Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.
Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and…
Shots:
Natera has acquired Foresight Diagnostics, adding its PhasED-Seq phased variant technology with LOD95 of 0.3ppm & detection below 0.1ppm, further enhancing Natera’s capabilities in solid tumor MRD and expanding its IP portfolio of >500 issued/pending patents
As per the agreement, Natera completed the acquisition in an all-stock transaction incl. $275M upfront & up to…

